Clinical trials: Age-Related Maculopathy
Geographic Atrophy Secondary to Age-related Macular Degeneration
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)
- Trial name
- NCT07214740
- Testing
- APL-2, Pegcetacoplan
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Macular Degeneration
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
This is a study in adults with geographic atrophy, an advanced form of age-related macular degeneration. The purpose of this study is to find out how well different doses of BI 754132 are tolerated.
- Trial name
- NCT04002310
- Testing
- BI 754132
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Age-related Macular Degeneration
Head to Head Study of Anti-VEGF Treatment.
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular…
- Trial name
- RELIANCE (NCT02577107)
- Testing
- ranibizumab, Conbercept
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Disease, Macular Degeneration
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
- Conditions
- Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
- Trial name
- NCT06394232
- Testing
- Eyecyte-RPE™
- Where
- 3 sites in India
- Volunteers
- 54 people
- Sponsor
- Eyestem Research Pvt. Ltd.
Age-Related Maculopathy
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
- Trial name
- NCT01577381
- Testing
- RN6G
- Where
- 83 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Wet Age-related Macular Degeneration
Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD
VEGF inhibitors (anti-VEGF),such as aflibercept has been shown to be safe and effective for treating nAMD and have demonstrated improvement in vision.
- Trial name
- NCT07178249
- Testing
- EXG202 injection
- Volunteers
- 60 people
- Sponsor
- Guangzhou Jiayin Biotech Ltd
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization…
- Trial name
- NCT00511706
- Testing
- dexamethasone, ranibizumab
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 243 people
- Sponsor
- Allergan
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
- Trial name
- VOYAGER (NCT05476926)
- Testing
- Faricimab, Port Delivery System with Ranibizumab
- Where
- 299 sites in United States, Argentina and 27 more
- Volunteers
- 6,000 people
- Sponsor
- Hoffmann-La Roche
Wet Age-related Macular Degeneration
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
Multicenter ，open-label, multi-dose study to evaluate the safety and tolerability in patients with wAMD treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody（SCT510A）
- Trial name
- NCT04564937
- Testing
- SCT510A
- Volunteers
- 66 people
- Sponsor
- Sinocelltech Ltd.
Exudative Age-related Macular Degeneration
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet age-related macular degeneration.
- Trial name
- RAMEN (NCT04640272)
- Testing
- RBM-007
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ribomic USA Inc
AMD
TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects
Subjects with secondary wet age-related macular degeneration(AMD) or recurrent subfoveal choroidal neovascularization (CNV) in only one study eye will be enrolled into the study.
- Trial name
- NCT03675880
- Testing
- TAB014
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Lee's Pharmaceutical Limited
Geographic Atrophy
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
Safety Assessment of APL-2 in Patients with Geographic Atrophy
- Trial name
- NCT03777332
- Testing
- PEGCETACOPLAN (APL-2)
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
- Trial name
- Super Tuscan (NCT07205887)
- Testing
- Remigromig, Aflibercept 2.0 mg
- Where
- 55 sites in United States
- Volunteers
- 160 people
- Sponsor
- EyeBiotech Ltd.
Wet Age-Related Macular Degeneration
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
This study evaluates the tolerability and safety of 3 months treatment with PTK787 tablets given daily. It also explores the efficacy of the compound in patients with wet age-related macular edema.
- Trial name
- ADVANCE (NCT00138632)
- Testing
- PTK787
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Novartis
Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion.
- Trial name
- MIVI-5 (NCT00913744)
- Testing
- Ocriplasmin
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 100 people
- Sponsor
- ThromboGenics
Macular Degeneration
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD.
- Trial name
- NCT00312351
- Testing
- Pegaptanib sodium
- Where
- United States
- Volunteers
- 262 people
- Sponsor
- Eyetech Pharmaceuticals
Age-Related Macular Degeneration
OcuDyne System in the Treatment of AMD
Feasibility of the OcuDyne OPTiC System in patients with late-stage non-exudative age-related macular degeneration.
- Trial name
- NCT05091476
- Testing
- OPTiC System
- Where
- 2 sites in Argentina
- Volunteers
- 17 people
- Sponsor
- OcuDyne, Inc.
Geographic Atrophy
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old.
- Trial name
- NCT06006585
- Testing
- BI 771716
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
- Trial name
- OASIS (NCT07660640)
- Testing
- observational study, VOY-101
- Where
- 4 sites in United States, Israel
- Volunteers
- 88 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Macular Edema, Retinal Vein Occlusion
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent…
- Trial name
- NCT01442064
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.